Skip to main content

Novel mechanisms of anti-hypertrophic effects from PDE5A inhibition

Background

Phosphodiesterase type-5 is a cGMP-selective PDE expressed in heart, and growing evidence supports its importance in modifying cardiac stress response signalling. Recent human studies have reported PDE5A myocyte expression notably in disease conditions such as hypertrophy and dilated heart failure. We have shown that upregulating PDE5A in isolated myocytes stimulates cellular hypertrophy. This is now demonstrated in vivo using a new tetracycline-controllable myocyte-targeted overexpression mouse model. Upregulation of PDE5A in myocytes lowers PKG activation, and results in gradual chamber dilation, hypertrophy, and dysfunction. In hearts from younger transgenic animals (without basal abnormalities), PDE5A overexpression worsens the response to pressure-overload stress. A major target of PDE5A-inhibitor mediated anti-hypertrophic signalling appears to be Gaq-receptor activation by both neurohumoral ligands and mechanical stimuli. Here we report several new mechanisms by which this is achieved.

Results

In one study, mice lacking the regulator of G-protein signalling 2 (RGS2) show profoundly worse responses to pressure-overload, with early hypertrophy, dilation, dysfunction, and lethality. Despite elevation of PKG in these hearts treated with sildenafil as in littermate controls, the RGS2-null heart does not respond to PDE5A inhibition (with less hypertrophy, improved function, etc.) whereas the controls do. PKG-RGS2 interaction is important to this signalling. In a second series of studies, we identified a novel PKG regulation of transient receptor potential canonical channel protein (TRPC6). TRPC6 has been shown to serve as a ligand and stretch responsive channel for Ca2+ conductance – that couples to Ca2+-calmodulin/calcineurin/NFAT activation. Recent evidence in embryonic aortic smooth muscle has shown TRPC6 can be PKG phosphorylated at T11, reducing conductance. We have found PKG also phosphorylates TRPC6 in myocytes, identifying two functional sites, and that this is coupled with changes in conductance modulation by cGMP/PKG and with antihypertrophic signalling effects of sildenafil linked to the suppression of NFAT activity induced by Gq-receptor agonists. Gain or loss of function phosphor-mutants confirm the functionality of this modulation by PKG.

Conclusion

As TRPC6 is also thought to play an important role in hypertension, and gain of function missense mutations lead to human glomerulosclerosis, the ability of sildenafil to suppress conductance may have broader implications beyond cardiac disease.

Author information

Affiliations

Authors

Corresponding author

Correspondence to David A Kass.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Kass, D.A., Nagayama, N., Zhang, M. et al. Novel mechanisms of anti-hypertrophic effects from PDE5A inhibition. BMC Pharmacol 9, S18 (2009). https://doi.org/10.1186/1471-2210-9-S1-S18

Download citation

Keywords

  • Glomerulosclerosis
  • Overexpression Mouse
  • Transient Receptor Potential Canonical Channel
  • Chamber Dilation
  • Recent Human Study